10:19:31 EST Wed 01 Feb 2023
Enter Symbol
or Name

Cannabis Summary for Dec. 6, 2022

2022-12-06 20:25 ET - Market Summary

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Stockwatch Business Reporter

The S&P/TSX Cannabis Index lost 6.45 to 43.98, while the CSE Composite Index lost 21.40 to 286.40. International cannabis reform advocates cheered as a country of over 50 million people moved closer to cannabis legalization. In Colombia today, a bill to legalize cannabis received overwhelming approval in a 56-3 vote in the Senate, mere weeks after clearing the lower Chamber of Representatives.

The bill is designed to rectify what Justice Minister Nestor Osuna has called a "failed war [on drugs] that was designed 50 years ago and, due to absurd prohibitionism, has brought us a lot of blood, armed conflict, mafias and crime." Specifically, the bill would amend Colombia's constitution to end cannabis prohibition for adults. It would also give lawmakers six months to establish rules for a regulated market.

The bill still faces a long road to enactment. Unlike regular bills, which generally require up to two debates in each chamber, this one seeks to amend the constitution, and must thus go through no fewer than eight debates spread out over two years (two consecutive legislative sessions). As a result, the bill is not anywhere close to heading to the President's desk just yet. The good news is that it will likely find a welcome reception if it does. President Gustavo Petro, who recently decried the "irrational war on drugs" during an address to the United Nations, has been a vocal advocate for ending drug criminalization since taking office in August.

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

© 2023 Canjex Publishing Ltd. All rights reserved.

Reader Comments - Comments are open to paying subscribers of Stockwatch and unmoderated, although libelous remarks, obscene language and impersonations may be deleted. Opinions expressed do not necessarily reflect the views of Stockwatch.
For information regarding Canadian libel law, please view the University of Ottawa's FAQ regarding Defamation and SLAPPs.